03261nas a2200445 4500000000100000008004100001653001600042653002600058653002100084653002500105653002300130653001900153653001500172653001600187653002500203653000900228653001500237653001100252653001600263653001100279653002600290653002000316653003000336653002100366653001100387653001000398653001500408100001600423700002400439700001500463700001900478700002000497700001300517700001100530245012300541300001100664490000700675520211900682022001402801 2011 d10aYoung Adult10aSocioeconomic Factors10aSex Distribution10aPatient Satisfaction10aPatient Compliance10aonchocerciasis10aMotivation10aMiddle Aged10aMedication adherence10aMale10aIvermectin10aHumans10aFilaricides10aFemale10aEpidemiologic Methods10aCost of Illness10aCommunity Health Services10aAge Distribution10aAfrica10aAdult10aAdolescent1 aOkeibunor J1 aAmuyunzu-Nyamongo M1 aOnyeneho N1 aTchounkeu YF L1 aManianga Célé1 aKabali A1 aLeak S00aWhere would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa. a608-210 v163 a

OBJECTIVES: To document peoples' perceptions of the benefits of taking ivermectin, as an important predictor of sustained compliance with long-term ivermectin treatment, and to identify the socio-demographic correlates of perceived benefits of ivermectin treatment.

METHODS: Multisite study in Cameroon, DRC, Nigeria and Uganda. A structured questionnaire was administered to 1600 persons randomly selected from household treatment records. Community leaders, community-directed drug distributors (CDDs) and health workers were interviewed using in-depth interview guides, while focus group discussions (FGDs) were held with community members to capture factors that reflected their perception of benefits of community-directed treatment with ivermectin (CDTI). Case histories of persons with special experiences with onchocerciasis were collected.

RESULTS: In this study, 84.7% of respondents indicated that ivermectin treatment has many benefits. The social benefits of CDTI included improved ability to work, peer acceptance and improved school attendance. Other individual benefits included self-respect/esteem, election to political office and improved relationship in the homes. The health benefits included improved skin texture and less ill health. Important demographic factors that influenced perception of the benefits of taking ivermectin, include marital status (P=0.012), age (P=0.029) and length of stay in onchocerciasis-endemic communities (P<0.001). Another factor was individual perception of susceptibility to onchocerciasis infection (P<0.0001).

CONCLUSION: A programmatic focus on the benefits of CDTI could provide a basis for motivating communities to comply with long-term treatment with ivermectin. The results illustrate the importance of capturing beneficiaries' perceptions towards CDTI as a resource for producing health education materials for increasing the sustainability ivermectin distribution in endemic countries.

 

 

 

 a1365-3156